Prognostic significance of programmed cell death-ligand 1 expression on immune cells and epithelial-mesenchymal transition expression in patients with hepatocellular carcinoma

被引:0
作者
Jung, Hae Il [1 ]
Ahn, Hyein [2 ]
Oh, Mee-Hye [2 ]
Yun, JongHyuk [1 ]
Lee, Hyunyong [1 ]
Bae, Sang Ho [1 ]
Kim, Yung Kil [1 ]
Kim, Sung Yong [1 ]
Baek, Moo-Jun [1 ]
Lee, Moon-Soo [1 ]
机构
[1] Soonchunhyang Univ, Cheonan Hosp, Coll Med, Dept Surg, 31 Suncheonhyang 6 gil, Cheonan 31151, South Korea
[2] Soonchunhyang Univ, Cheonan Hosp, Coll Med, Dept Pathol, Cheonan, South Korea
基金
新加坡国家研究基金会;
关键词
Epithelial-mesenchymal transition; Hepatocellular carcinoma; Prognosis; Programmed cell death 1 ligand 2 protein; Tumor-infiltrating lymphocytes; PD-L1; EXPRESSION; POOR SURVIVAL; INFILTRATION;
D O I
10.4174/astr.2023.105.5.297
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose: Immune checkpoint inhibitors (ICIs) have been shown significant oncological improvements in several cancers. However, ICIs are still in their infancy in hepatocellular carcinoma (HCC). Programmed cell death-ligand 1 (PD-L1), tumorinfiltrating cytes (TILs), and epithelial-mesenchymal transition (EMT) have been known as prognostic factors in HCC. Therefore, we have focused on identifying the molecular mechanisms between each marker to evaluate a predictive role. Methods: Formalin-fixed paraffin-embedded samples were obtained from 166 patients with HCC who underwent surgery. The expression of PD-L1 and TILs and EMT marker were evaluated by immunohistochemical analysis. Results: The multivariate analysis showed that TIL expression (hazard ratio [HR], 0.483; 95% confidence interval [CI], 0.269-0.866; P = 0.015) were independent prognostic factors for overall survival. The prognostic factors for disease-free survival were EMT marker expression (HR, 1.565; 95% CI, 1.019-2.403; P = 0.005). Patients with high expression of TILs had significantly better survival compared to patients with low expression (P = 0.023). Patients who were TIL+/EMT- showed a significantly better prognosis than those who were TIL-/EMT+ (P = 0.049). Conclusion: This study demonstrates that PD-L1 expression of TILs is closely associated with EMT marker expression in HCC. Clinical
引用
收藏
页码:297 / 309
页数:13
相关论文
共 50 条
  • [41] Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
    Motohide Uemura
    Noboru Nakaigawa
    Naoto Sassa
    Katsunori Tatsugami
    Kenichi Harada
    Toshinari Yamasaki
    Nobuaki Matsubara
    Takuya Yoshimoto
    Yuki Nakagawa
    Tamaki Fukuyama
    Mototsugu Oya
    Nobuo Shinohara
    Hirotsugu Uemura
    Toyonori Tsuzuki
    International Journal of Clinical Oncology, 2021, 26 : 2073 - 2084
  • [42] Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
    Ishii, Hidenobu
    Azuma, Koichi
    Kawahara, Akihiko
    Yamada, Kazuhiko
    Imamura, Yohei
    Tokito, Takaaki
    Kinoshita, Takashi
    Kage, Masayoshi
    Hoshino, Tomoaki
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (03) : 426 - 430
  • [43] Programmed death-ligand expression and lymph nodeinvolvement in penile squamous cell carcinoma
    Peyroteo, Ines
    Santos, Filipa
    Marialva, Celso
    Ramos, Rodrigo
    ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA, 2024, 96 (03)
  • [44] Clinical Significance of Programmed Death Ligand-1 Expression in Esophageal Squamous Cell Carcinoma
    Ito, Nozomi
    Tsujimoto, Hironori
    Horiguchi, Hiroyuki
    Shimazaki, Hideyuki
    Miyazaki, Hiromi
    Saitoh, Daizoh
    Kishi, Yoji
    Ueno, Hideki
    JOURNAL OF SURGICAL RESEARCH, 2020, 251 : 321 - 328
  • [45] Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis
    Ouyang, Yushu
    Liu, Wendao
    Zhang, Ningning
    Yang, Xiaobing
    Li, Jinwei
    Long, Shunqin
    CANCER MEDICINE, 2021, 10 (20): : 7021 - 7039
  • [46] Programmed Death 1 Ligand Expression in the Monocytes of Patients with Hepatocellular Carcinoma Depends on Tumor Progression
    Asai, Akira
    Yasuoka, Hidetaka
    Matsui, Masahiro
    Tsuchimoto, Yusuke
    Fukunishi, Shinya
    Higuchi, Kazuhide
    CANCERS, 2020, 12 (08) : 1 - 14
  • [47] The Prognostic Role of Programmed Death-Ligand 1 in Nasopharyngeal Carcinoma
    Wotman, Michael
    Herman, Saori W.
    Costantino, Peter
    Tham, Tristan
    LARYNGOSCOPE, 2020, 130 (11) : 2598 - 2606
  • [48] Assessment of Programmed Death-Ligand 1 Expression and Tumor-Associated Immune Cells in Pediatric Cancer Tissues
    Majzner, Robbie G.
    Simon, Jason S.
    Grosso, Joseph F.
    Martinez, Daniel
    Pawel, Bruce R.
    Santi, Mariarita
    Merchant, Melinda S.
    Geoerger, Birgit
    Hezam, Imene
    Marty, Virginie
    Vielh, Phillippe
    Daugaard, Mads
    Sorensen, Poul H.
    Mackall, Crystal L.
    Maris, John M.
    CANCER, 2017, 123 (19) : 3807 - 3815
  • [49] The expression of programmed death-ligand 1 in patients with invasive breast cancer
    Meng, Yi
    Wu, Hongyan
    Yao, Yongzhong
    Li, Rong
    GLAND SURGERY, 2020, 9 (06) : 2106 - 2115
  • [50] The pattern and clinicopathological correlates of programmed death-ligand 1 expression in cutaneous squamous cell carcinoma
    Schaper, K.
    Koether, B.
    Hesse, K.
    Satzger, I.
    Gutzmer, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (05) : 1354 - 1356